GlassScriptPhysician profile
Daniel Robert Amoruso
NPI 1528386380
$8,863.36
in general payments reported to CMS, 2019-2025
41 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $840 · 2021: $1,006 · 2022: $1,436 · 2023: $1,149 · 2024: $1,777 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,117 · Entertainment: $15.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,117.09 |
| Entertainment | $15.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,240.95 | 2019-2025 | Dragonfly Opstar, Diamondback Coronary, Cardiomems |
| Boston Scientific Corporation | $1,380.38 | 2019-2025 | Rotapro, Avvigo Guidance System, Opticross |
| Cardiovascular Systems INC. | $692.77 | 2019-2023 | Diamondback Coronary |
| Abiomed | $669.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $658.72 | 2019-2025 | |
| Amgen INC. | $410.27 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $224.98 | 2019-2024 | Xarelto |
| Atricure, INC. | $200.60 | 2019-2025 | Atriclip Laa Exclusion System |
| Astrazeneca Pharmaceuticals LP | $199.86 | 2019-2025 | Farxiga |
| Pfizer INC. | $193.68 | 2022-2025 | |
| Medtronic, INC. | $180.89 | 2022-2025 | Ffrangio, Corevalve Evolut R, Telescope |
| Merck Sharp & Dohme LLC | $166.98 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $163.48 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.04 | 2021-2025 | Jardiance |
| Saranas, INC. | $156.19 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $150.67 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Heartflow, INC. | $119.17 | 2019-2025 | |
| Chiesi USA, INC. | $117.16 | 2021-2022 | |
| Esperion Therapeutics, INC. | $91.28 | 2021-2024 | Nexletol |
| Novo Nordisk INC | $82.00 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Cardiva Medical, INC. | $79.64 | 2021-2025 | Optowire |
| Baxter Healthcare | $52.87 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $45.13 | 2021-2025 | Camzyos |
| Arbor Pharmaceuticals, INC. | $43.34 | 2019 | |
| Penumbra, INC. | $39.36 | 2021-2022 | |
| Glaxosmithkline, LLC. | $36.21 | 2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $34.43 | 2019-2022 | |
| Cvrx, INC. | $32.10 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $30.44 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $29.99 | 2021-2023 | |
| Irhythm Technologies, INC. | $22.85 | 2023 | Zio Xt Patch |
| Scpharmaceuticals INC. | $20.76 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $17.00 | 2025 | Uptravi |
| Lilly USA, LLC | $16.07 | 2025 | Mounjaro, Zepbound |
| Cordis US Corp. | $15.64 | 2024 | Mynx Venous Vcd |
| Opsens INC. | $15.33 | 2023 | Optowire |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2019 | |
| Amryt Pharma Holdings LTD | $14.60 | 2021 | |
| Medtronic Vascular, INC. | $14.60 | 2019 | |
| Stryker Corporation | $14.39 | 2025 | Flowtriever |
| Kiniksa Pharmaceuticals, LTD. | $14.31 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Amoruso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.